Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 9/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26676818 | 0.81 | HTR7 (0.47) | HTR7HTR6OPRM1OPRD1OPRK1 | |
| SCHEMBL30909064 | 0.81 | OPRM1 (0.58) | HTR7HTR6OPRM1OPRD1OPRK1 | |
| SCHEMBL6775059 | 0.81 | OPRM1 (0.58) | HTR7HTR6OPRM1OPRD1OPRK1 | |
| SCHEMBL31324662 | 0.80 | HTR7 (0.51) | HTR7HTR6NOS3NOS1NOS2 | |
| Methane SCHEMBL28163314 | 0.79 | HTR7 (0.50) | HTR7HTR6NOS3NOS1NOS2 | |
| SCHEMBL28674631 | 0.78 | HTR7 (0.47) | HTR7HTR6OPRM1OPRD1OPRK1 | |
| SCHEMBL30909174 | 0.77 | OPRM1 (0.56) | HTR7HTR6OPRM1OPRD1OPRK1 | |
| SCHEMBL7570882 | 0.76 | OPRM1 (0.39) | HTR6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6742084 | 0.76 | HTR1A (0.51) | HTR7HTR6OPRM1OPRD1OPRK1 | |
| SCHEMBL20612465 | 0.74 | HTR1A (0.44) | HTR7HTR6NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | HTR7 3/4885HTR6 237/4885OPRM1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.